In vitro and in vivo activities of novel, semisynthetic thiopeptide inhibitors of bacterial elongation factor Tu

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5277-5283

  Leeds, J A ^a   LaMarche, M J ^b   Brewer, J T ^b   Bushell, S M ^b   Deng, G ^a,e   Dewhurst, J M ^b   Dzink Fox, J ^a   Gangl, E ^b,f   Jain, A ^d   Lee, L ^a   Lilly, M ^a   Manni, K ^a   Mullin, S ^a   Neckermann, G ^a,f   Osborne, C ^a   Palestrant, D ^c,g   Patane, M A ^b,h   Raimondi, A ^a,i   Ranjitkar, S ^a   Rann, E M ^b   Sachdeva, M ^a   Shao, J ^b   Tiamfook, S ^a   Whitehead, L ^b   Yu, D ^a   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Global Discovery Chemistry   (United States)

^c Center for Proteomic Chemistry   (United States)

^d NOVARTIS PHARMA K K   (Japan)

^e Sanofi Aventis   (United States)

^f ASTRAZENECA   (United Kingdom)

^g THIRD ROCK VENTURES   (United States)

^h Jade Therapeutics Inc   (United States)

ⁱ EPIZYME INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; DAPTOMYCIN; ELONGATION FACTOR TU; GE 2270A; LINEZOLID; PUROMYCIN; TETRACYCLINE; THIOPEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG STRUCTURE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; IN VITRO STUDY; IN VIVO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CELL SURVIVAL; FEMALE; HEP G2 CELLS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICE; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; PEPTIDE ELONGATION FACTOR TU; PEPTIDES, CYCLIC; STAPHYLOCOCCAL INFECTIONS; THIAZOLES;

EID: 80054697983     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00582-11     Document Type: Article

References (25)

1. Anborgh, P. H., G. W. Swart, and A. Parmeggiani. 1991. Kirromycin-induced modifications facilitate the separation of EF-Tu species and reveal intermolecular interactions. FEBS Lett. 292:232-236.
2. Barton, E., and A. MacGowan. 2009. Future treatment options for Gram-positive infections: looking ahead. Clin. Microbiol. Infect. 15(Suppl. 6): 17-25.
3. Berridge, M. V., P. M. Herst, and A. S. Tan. 2005. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol. Annu. Rev. 11:127-152. (Pubitemid 41510276)
4. Boucher, H. W., et al. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
5. Butler, M. S. 2005. Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep. 22:162-195. (Pubitemid 40589045)
6. Clough, J., et al. 2003. Combinatorial modification of natural products: synthesis and in vitro analysis of derivatives of thiazole peptide antibiotic GE2270 A: A-ring modifications. Bioorg. Med. Chem. Lett. 13:3409-3414. (Pubitemid 37141398)
7. Clinical and Laboratory Standards Institute. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Darken, M. A. 1964. Puromycin inhibition of protein synthesis. Pharmacol. Rev. 16:223-243.
9. Deng, G., et al. 2010. Biophysical characterization of novel thiopeptide (TP)- derived inhibitors of bacterial elongation factor Tu (EF-Tu), abstr. F-1204. 50th Intersci. Conf. Antimicrob. Agents Chemother.
10. Goldstein, B. P., et al. 1993. In vitro antimicrobial activity of a new antibiotic, MDL 62,879 (GE2270 A). Antimicrob. Agents Chemother. 37:741-745. (Pubitemid 23096871)
11. Hiramatsu, K., et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. (Pubitemid 27341646)
12. King, A., L. Bethune, and I. Phillips. 1993. In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria. Antimicrob. Agents Chemother. 37:746-749. (Pubitemid 23096872)
13. LaMarche, M. J., et al. 2010. Antibacterial lead optimization of the GE2270 class of thiopeptides: identification of development candidates, abstr. F1- 2086a. 50th Intersci. Conf. Antimicrob. Agents Chemother.
14. Reference deleted.
15. LaMarche, M. J., et al. 2011. 4-Aminothiazolyl analogues of GE2270 A: antibacterial lead finding. J. Med. Chem. 54:2517-2521.
16. Landini, P., et al. 1992. Inhibition of bacterial protein synthesis by elongation- factor-Tu-binding antibiotics MDL 62,879 and efrotomycin. Biochem. J. 283(Pt. 3):649-652.
17. Leeds, J. A., E. K. Schmitt, and P. Krastel. 2006. Recent developments in antibacterial drug discovery: microbe-derived natural products: from collection to the clinic. Expert Opin. Invest. Drugs 15:211-226. (Pubitemid 43338143)
18. Li, J. W., and J. C. Vederas. 2009. Drug discovery and natural products: end of an era or an endless frontier? Science 325:161-165.
19. Lociuro, S., et al. 1997. Antimicrobial activities of chemically modified thiazolyl peptide antibiotic MDL 62,879 (GE2270A). J. Antibiot. (Tokyo) 50: 344-349. (Pubitemid 27223127)
20. Morris, R. P., et al. 2009. Ribosomally synthesized thiopeptide antibiotics targeting elongation factor Tu. J. Am. Chem. Soc. 131:5946-5955.
21. Parmeggiani, A., and P. Nissen. 2006. Elongation factor Tu-targeted antibiotics: four different structures, two mechanisms of action. FEBS Lett. 580: 4576-4581. (Pubitemid 44189384)
22. Roemer, T., et al. 2011. Confronting the challenges of natural product-based antifungal discovery. Chem. Biol. 18:148-164.
23. Schopfer, U., et al. 2009. Hypothesis-driven screening. Methods Mol. Biol. 575:297-316.
24. Wolf, H., G. Chinali, and A. Parmeggiani. 1974. Kirromycin, an inhibitor of protein biosynthesis that acts on elongation factor Tu. Proc. Natl. Acad. Sci. U. S. A. 71:4910-4914.
25. Zuurmond, A. M., et al. 2000. GE2270A-resistant mutations in elongation factor Tu allow productive aminoacyl-tRNA binding to EFTu. GTP.GE2270A complexes. J. Mol. Biol. 304:995-1005.